Pharmacogenomics is the basis of personalized medicine which will
be the medicine of the future. Through both reducing the numbers of
adverse drug reactions and improving the use of existing drugs in
targeted populations, pharmacogenomics represents a real advance on
traditional therapeutic drug monitoring.
Pharmacogenomics in Clinical Therapeutics provides an
introduction to the principles of pharmacogenomics before
addressing the pharmacogenomic aspects of key therapeutic areas
such as warfarin therapy, cancer chemotherapy, therapy with
immunosuppressants, antiretroviral therapy, and psychoactive drugs.
It also includes methods of pharmacogenomic testing and the
pharmacogenomic aspects of drug-drug interactions.
From a team of expert contributors, Pharmacogenomics in
Clinical Therapeutics is a comprehensive overview of the
current state of pharmacogenomics in pharmacotherapy for all
clinicians, pharmacologists and clinical laboratory professionals.
It is also a guide for practicing clinicians and health care
professionals to the basic principles of pharmacogenomics,
laboratory tests currently available to aid clinicians, and the
future promise of this developing field.
Tabella dei contenuti
List of Contributors, vii
Preface, ix
1 Pharmacogenomics Principles: Introduction to Personalized
Medicine, 1
Parvaz Madadi, Ph D and Gideon Koren, MD
2 Traditional Therapeutic Drug Monitoring and Pharmacogenomics:
Are They Complementary? 15
Christine L.H. Snozek, Ph D, Loralie J. Langman, Ph D, and Amitava
Dasgupta, Ph.D
3 Pharmacogenomics Aspect of Warfarin Therapy, 26
Matthew D. Krasowski, MD, Ph D
4 Pharmacogenetics and Cancer Chemotherapy, 39
Christine L.H. Snozek
5 Pharmacogenomic Considerations in Anesthesia and Pain
Management, 53
Christine M. Formea, Pharm D and Wayne T. Nicholson, MD,
Pharm D
6 Pharmacogenomics of Immunosuppressants, 70
Nicolas Picard, Pharm D, Ph D and Pierre Marquet, MD, Ph D
7 Pharmacogenomics of Cardiovascular Drugs, 98
Linnea M. Baudhuin, Ph D
8 Pharmacogenomic Aspects of Antiretroviral Therapy, 127
Natella Y. Rakhmanina, MD, Ph D and John N. van den Anker, MD,
Ph D
9 Pharmacogenetics of Psychoactive Drugs, 144
Jorge L. Sepulveda, MD, Ph D
10 Pharmacogenomic Aspects of Adverse Drug-Drug
Interactions, 176
Loralie J. Langman, Ph D and Christine L.H. Snozek, Ph D
11 Microarray Technology and Other Methods in Pharmacogenomics
Testing, 185
Jorge L. Sepulveda, MD, Ph D
12 Pharmacogenetic Testing in the Clinical Laboratory
Environment, 201
Mark P. Borgman, Ph D and Mark W. Linder, Ph D
Index, 225
Circa l’autore
Amitava Dasgupta, Ph.D, DABCC, FACB, Professor of Pathology and Laboratory Medicine, University of Texas Health Sciences Center at Houston, Houston, TX.
Loralie J. Langman, Ph.D, DABCC, FACB, Associate Professor of Laboratory Medicine, Mayo Clinic, Rochester, MN.